Abstract |
Wilex AG, in collaboration with the Ludwig Institute for Cancer Research, is developing WX-G250, a kappa light chain chimeric antibody derived from the variable region of the mouse monoclonal antibody G250, for the potential treatment of biliary cancer and renal cell carcinoma (RCC). The antibody is currently undergoing phase II clinical trials for RCC and preclinical development for biliary cancer.
|
Authors | Roger H Kennett |
Journal | Current opinion in molecular therapeutics
(Curr Opin Mol Ther)
Vol. 5
Issue 1
Pg. 70-5
(Feb 2003)
ISSN: 1464-8431 [Print] England |
PMID | 12669474
(Publication Type: Evaluation Study, Journal Article)
|
Chemical References |
- Antibodies, Monoclonal
- Antibodies, Neoplasm
- G250 monoclonal antibody
- Iodine Radioisotopes
- Recombinant Fusion Proteins
|
Topics |
- Animals
- Antibodies, Monoclonal
(therapeutic use)
- Antibodies, Neoplasm
(immunology, therapeutic use)
- Carcinoma, Renal Cell
(therapy)
- Clinical Trials, Phase II as Topic
- Gallbladder Neoplasms
(therapy)
- Humans
- Iodine Radioisotopes
(therapeutic use)
- Kidney Neoplasms
(therapy)
- Radioimmunotherapy
- Recombinant Fusion Proteins
(immunology, therapeutic use)
- Technology Assessment, Biomedical
|